Bruker’s Microbiology and Infection Diagnostics division has launched the MyGenius PRO fully automated, sample-to-answer molecular diagnostics system in Europe.
The high-throughput molecular diagnostics system, which is based on PCR (polymerase chain reaction) technology, made its debut at ESCMID Global 2026.
Designed for infectious disease diagnostics, the new sample-to-answer (S2A) system enables higher throughput, continuous loading of samples, consumables, and reagents, and supports random-access operation. Like the successful medium-throughput BeGenius system, which excels at assay and sample matrix flexibility, the new higher-throughput MyGenius PRO automates the entire workflow - from patient sample to diagnostic result - enhancing laboratory efficiency and supporting higher-throughput volume testing needs.
At launch, the MyGenius PRO IVDR menu will include assays for cytomegalovirus (CMV) and Epstein-Barr virus (EBV) from whole blood, and BK virus (BKV) from urine, supporting diagnostic testing in immunocompromised patients. Rapid menu expansion, including human immunodeficiency virus type 1 (HIV-1), hepatitis B virus (HBV), hepatitis C virus (HCV), human herpesvirus 6 (HHV-6) IVDR assays, and additional sample matrices, are planned throughout 2026.
The MyGenius PRO platform was developed in a collaboration between ELITechGroup, a Bruker company, and Hitachi High Tech-Corporation, combining complementary expertise in molecular assays, automation and engineering. Hitachi High-Tech will introduce the platform under the tradename LABOSPECT GA-5 in Japan. This system comes with Bruker molecular diagnostic assays for infectious disease testing in accordance with Japanese diagnostic regulations.
The launch of MyGenius PRO marks a new chapter in Bruker’s Microbiology and Infection Diagnostics molecular diagnostics strategy, further expanding a portfolio that includes InGenius, BeGenius, a rapidly growing CE-IVD assay menu, and novel LiquidArray assays for advanced multiplexing and more affordable syndromic panel testing.